Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke

Acta Neuropathologica

Volumn 131, Issue 5, 2016, Pages 775-791

  Clausen, Bettina Hjelm ^a   Lambertsen, Kate Lykke ^a   Dagnæs Hansen, Frederik ^c   Babcock, Alicia Anne ^a   von Linstow, Christian Ulrich ^a   Meldgaard, Michael ^a,d   Kristensen, Bjarne Winther ^e   Deierborg, Tomas ^b   Finsen, Bente ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b LUND UNIVERSITY   (Sweden)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Focal cerebral ischemia; Human brain; IL 1 ; Inflammation; Macrophages; Microglia

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; GLIAL FIBRILLARY ACIDIC PROTEIN; GREEN FLUORESCENT PROTEIN; NEUROPROTECTIVE AGENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BRAIN CORTEX; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL THERAPY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL STROKE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MICROGLIA; MOUSE; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROKE PATIENT; TREATMENT OUTCOME; WHOLE BODY RADIATION; ANIMAL; BIOLOGICAL THERAPY; BRAIN; BRAIN INFARCTION; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUSCLE STRENGTH; PATHOLOGY; PHYSIOLOGY; PROCEDURES; STROKE; TIME FACTOR; TRANSGENIC MOUSE;

ANIMALS; BRAIN; BRAIN INFARCTION; CELL- AND TISSUE-BASED THERAPY; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FEMALE; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; GREEN FLUORESCENT PROTEINS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE STRENGTH; NEUROPROTECTIVE AGENTS; STROKE; TIME FACTORS;

EID: 84957660783     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-016-1541-5     Document Type: Article

References (64)

1. Abbate A, Salloum FN, Van Tassell BW, Vecile E, Toldo S, Seropian I, Mezzaroma E, Dobrina A (2011) Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS One 6:e27923. doi:10.1371/journal.pone.0027923
2. Allen NJ, Barres B (2009) Glia—more than just brain glue. Nature 457:675–677. doi:10.1038/457675a
3. Babcock AA, Wirenfeldt M, Holm T, Nielsen HH, Dissing-Olesen L, Toft-Hansen H, Millward JM, Landmann R, Rivest S, Finsen B et al (2006) Toll-like receptor 2 signaling in response to brain injury: an innate bridge to neuroinflammation. J Neurosci 26:12826–12837
4. Bach A, Clausen BH, Moller M, Vestergaard B, Chi CN, Round A, Sorensen PL, Nissen KB, Kastrup JS, Gajhede M et al (2012) A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. Proc Natl Acad Sci USA 109:3317–3322. doi:10.1073/pnas.1113761109
5. Berrocal Y, Pearse DD, Singh A, Andrade CM, McBroom JS, Puentes R, Eaton MJ (2007) Social and environmental enrichment improves sensory and motor recovery after severe contusive spinal cord injury in the rat. J Neurotrauma 24:1761–1772. doi:10.1089/neu.2007.0327
6. Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ (2001) Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 21:5528–5534
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
8. Buttini M, Sauter A, Boddeke HW (1994) Induction of interleukin-1 beta mRNA after focal cerebral ischaemia in the rat. Brain Res Mol Brain Res 23:126–134
9. Clausen B, Degn M, Martin N, Couch Y, Karimi L, Ormhoj M, Mortensen ML, Gredal H, Gardiner C, Sargent II et al (2014) Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. J Neuroinflammation 11:203. doi:10.1186/PREACCEPT-2982253041347736
10. Clausen BH, Lambertsen KL, Babcock AA, Holm TH, Dagnaes-Hansen F, Finsen B (2008) Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation 5:46. doi:10.1186/1742-2094-5-46
11. Clausen BH, Lambertsen KL, Finsen B (2006) Glyceraldehyde-3-phosphate dehydrogenase versus toluidine blue as a marker for infarct volume estimation following permanent middle cerebral artery occlusion in mice. Exp Brain Res 175:60–67. doi:10.1007/s00221-006-0526-3
12. Clausen BH, Lambertsen KL, Meldgaard M, Finsen B (2005) A quantitative in situ hybridization and polymerase chain reaction study of microglial-macrophage expression of interleukin-1beta mRNA following permanent middle cerebral artery occlusion in mice. Neuroscience 132:879–892. doi:10.1016/j.neuroscience.2005.01.031
13. Cullinan EB, Kwee L, Nunes P, Shuster DJ, Ju G, McIntyre KW, Chizzonite RA, Labow MA (1998) IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 161:5614–5620
14. Dahlrot RH, Sorensen MD, Rosager AM, Hellwege S, Bangso JA, Rosenberg T, Petterson SA, Klitkou J, Fosmark S, Hansen S et al (2014) Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. CNS Oncol 3:287–298. doi:10.2217/cns.14.30
15. Davies CA, Loddick SA, Toulmond S, Stroemer RP, Hunt J, Rothwell NJ (1999) The progression and topographic distribution of interleukin-1beta expression after permanent middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 19:87–98
16. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103:239–252
17. de Haas AH, Boddeke HW, Biber K (2008) Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia 56:888–894. doi:10.1002/glia.20663
18. del Zoppo GJ, Sharp FR, Heiss WD, Albers GW (2011) Heterogeneity in the penumbra. J Cereb Blood Flow Metab 31:1836–1851. doi:10.1038/jcbfm.2011.93
19. Denes A, Wilkinson F, Bigger B, Chu M, Rothwell NJ, Allan SM (2013) Central and haematopoietic interleukin-1 both contribute to ischaemic brain injury. Disease Models Mech 6:1043–1048. doi:10.1242/dmm.011601
20. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720–3732. doi:10.1182/blood-2010-07-273417
21. Docagne F, Campbell SJ, Bristow AF, Poole S, Vigues S, Guaza C, Perry VH, Anthony DC (2005) Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation. Eur J Neurosci 21:1205–1214. doi:10.1111/j.1460-9568.2005.03965.x
22. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G et al (2014) Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384:1929–1935. doi:10.1016/S0140-6736(14)60584-5
23. Fettelschoss A, Kistowska M, LeibundGut-Landmann S, Beer HD, Johansen P, Senti G, Contassot E, Bachmann MF, French LE, Oxenius A et al (2011) Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc Natl Acad Sci USA 108:18055–18060. doi:10.1073/pnas.1109176108
24. Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S, Hutchinson P, Grainger S, King A, Hopkins SJ et al (2011) Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab 31:439–447. doi:10.1038/jcbfm.2010.103
25. Giunti D, Parodi B, Usai C, Vergani L, Casazza S, Bruzzone S, Mancardi G, Uccelli A (2012) Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1. Stem Cells 30:2044–2053. doi:10.1002/stem.1174
26. Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, Catalano MA, Wolff SM, Dinarello CA (1992) Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4:353–360
27. Gregersen R, Lambertsen K, Finsen B (2000) Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 20:53–65
28. Gueorguieva I, Clark SR, McMahon CJ, Scarth S, Rothwell NJ, Tyrrell PJ, Hopkins SJ, Rowland M (2008) Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol 65:317–325. doi:10.1111/j.1365-2125.2007.03026.x
29. Gutierrez-Fernandez M, Fuentes B, Rodriguez-Frutos B, Ramos-Cejudo J, Vallejo-Cremades MT, Diez-Tejedor E (2012) Trophic factors and cell therapy to stimulate brain repair after ischaemic stroke. J Cell Mol Med 16:2280–2290. doi:10.1111/j.1582-4934.2012.01575.x
30. Hanisch UK (2013) Functional diversity of microglia—how heterogeneous are they to begin with? Frontiers in cellular neuroscience 7:65. doi:10.3389/fncel.2013.00065
31. Hermansen SK, Christensen KG, Jensen SS, Kristensen BW (2011) Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem 59:391–407. doi:10.1369/0022155411400867
32. Hirsch E, Irikura VM, Paul SM, Hirsh D (1996) Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci USA 93:11008–11013
33. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, Nishihara M, Takahashi M, Iwakura Y (1998) Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 187:1463–1475
34. Hutchinson PJ, O’Connell MT, Rothwell NJ, Hopkins SJ, Nortje J, Carpenter KL, Timofeev I, Al-Rawi PG, Menon DK, Pickard JD (2007) Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra. J Neurotrauma 24:1545–1557. doi:10.1089/neu.2007.0295
35. Inácio AR, Ruscher K, Leng L, Bucala R, Deierborg T (2011) Macrophage migration inhibitory factor promotes cell death and aggravates neurologic deficits after experimental stroke. J Cereb Blood Flow Metab 31:1093–1106. doi: 10.1038/jcbfm.2010.194
36. Irikura VM, Lagraoui M, Hirsh D (2002) The epistatic interrelationships of IL-1, IL-1 receptor antagonist, and the type I IL-1 receptor. J Immunol 169:393–398
37. Kalladka D, Muir KW (2014) Brain repair: cell therapy in stroke. Stem Cells Cloning 7:31–44. doi:10.2147/SCCAA.S38003
38. Klementiev B, Li S, Korshunova I, Dmytriyeva O, Pankratova S, Walmod PS, Kjaer LK, Dahllof MS, Lundh M, Christensen DP et al (2014) Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist. J Neuroinflammation 11:27. doi:10.1186/1742-2094-11-27
39. Lambertsen KL, Biber K, Finsen B (2012) Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 32:1677–1698. doi:10.1038/jcbfm.2012.88
40. Lambertsen KL, Clausen BH, Babcock AA, Gregersen R, Fenger C, Nielsen HH, Haugaard LS, Wirenfeldt M, Nielsen M, Dagnaes-Hansen F et al (2009) Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J Neurosci 29:1319–1330. doi:10.1523/JNEUROSCI.5505-08.2009
41. Lambertsen KL, Gramsbergen JB, Sivasaravanaparan M, Ditzel N, Sevelsted-Moller LM, Olivan-Viguera A, Rabjerg M, Wulff H, Kohler R (2012) Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. PLoS One 7:e47744. doi:10.1371/journal.pone.0047744
42. Lambertsen KL, Ostergaard K, Clausen BH, Hansen S, Stenvang J, Thorsen SB, Meldgaard M, Kristensen BW, Hansen PB, Sorensen GL et al (2014) No effect of ablation of surfactant protein-D on acute cerebral infarction in mice. J Neuroinflammation 11:123. doi:10.1186/1742-2094-11-123
43. Loddick SA, Wong ML, Bongiorno PB, Gold PW, Licinio J, Rothwell NJ (1997) Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochem Biophys Res Commun 234:211–215
44. Luheshi NM, Kovacs KJ, Lopez-Castejon G, Brough D, Denes A (2011) Interleukin-1alpha expression precedes IL-1beta after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues. J Neuroinflammation 8:186. doi:10.1186/1742-2094-8-186
45. Madsen PM, Clausen BH, Degn M, Thyssen S, Kristensen LK, Svensson M, Ditzel N, Finsen B, Deierborg T, Brambilla Ret al (2015) Genetic ablation of soluble tumor necrosis factor with preservation of membrane tumor necrosis factor is associated with neuroprotection after focal cerebral ischemia. J Cereb Blood Flow Metab. doi: 10.1177/0271678X15610339
46. Maysami S, Wong R, Pradillo JM, Denes A, Dhungana H, Malm T, Koistinaho J, Orset C, Rahman M, Rubio Met al (2015) A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke. J Cereb Blood Flow Metab. doi: 10.1177/0271678X15606714
47. Merhi-Soussi F, Berti M, Wehrle-Haller B, Gabay C (2005) Intracellular interleukin-1 receptor antagonist type 1 antagonizes the stimulatory effect of interleukin-1 alpha precursor on cell motility. Cytokine 32:163–170. doi:10.1016/j.cyto.2005.09.004
48. Moniche F, Montaner J, Gonzalez-Marcos JR, Carmona M, Pinero P, Espigado I, Cayuela A, Escudero I, de la Torre-Laviana FJ, Boada C et al (2014) Intra-arterial bone marrow mononuclear cell transplantation correlates with GM-CSF, PDGF-BB, and MMP-2 serum levels in stroke patients: results from a clinical trial. Cell Transplant 23(Suppl 1):S57–S64. doi:10.3727/096368914X684934
49. Novrup HG, Bracchi-Ricard V, Ellman DG, Ricard J, Jain A, Runko E, Lyck L, Yli-Karjanmaa M, Szymkowski DE, Pearse DD et al (2014) Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. J Neuroinflammation 11:159. doi:10.1186/s12974-014-0159-6
50. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 104:11002–11007. doi:10.1073/pnas.0704421104
51. Perego C, Fumagalli S, De Simoni MG (2011) Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J Neuroinflammation 8:174. doi:10.1186/1742-2094-8-174
52. Pinteaux E, Rothwell NJ, Boutin H (2006) Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia 53:551–556. doi:10.1002/glia.20308
53. Prinz M, Priller J, Sisodia SS, Ransohoff RM (2011) Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 14:1227–1235. doi:10.1038/nn.2923
54. Qian J, Zhu L, Li Q, Belevych N, Chen Q, Zhao F, Herness S, Quan N (2012) Interleukin-1R3 mediates interleukin-1-induced potassium current increase through fast activation of Akt kinase. Proc Natl Acad Sci USA 109:12189–12194. doi:10.1073/pnas.1205207109
55. Qu C, Li W, Shao Q, Dwyer T, Huang H, Yang T, Liu G (2013) c-Jun N-terminal kinase 1 (JNK1) is required for coordination of netrin signaling in axon guidance. J Biol Chem 288:1883–1895. doi:10.1074/jbc.M112.417881
56. Relton JK, Martin D, Thompson RC, Russell DA (1996) Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 138:206–213
57. Savitz SI, Misra V, Kasam M, Juneja H, Cox CS Jr, Alderman S, Aisiku I, Kar S, Gee A, Grotta JC (2011) Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol 70:59–69. doi:10.1002/ana.22458
58. Sedgwick JD, Schwender S, Imrich H, Dorries R, Butcher GW, ter Meulen V (1991) Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci USA 88:7438–7442
59. Shen LH, Li Y, Chen J, Cui Y, Zhang C, Kapke A, Lu M, Savant-Bhonsale S, Chopp M (2007) One-year follow-up after bone marrow stromal cell treatment in middle-aged female rats with stroke. Stroke 38:2150–2156. doi:10.1161/STROKEAHA.106.481218
60. Smith CJ, Emsley HC, Udeh CT, Vail A, Hoadley ME, Rothwell NJ, Tyrrell PJ, Hopkins SJ (2012) Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine 58:384–389. doi:10.1016/j.cyto.2012.02.016
61. Spulber S, Bartfai T, Schultzberg M (2009) IL-1/IL-1ra balance in the brain revisited—evidence from transgenic mouse models. Brain Behav Immun 23:573–579. doi:10.1016/j.bbi.2009.02.015
62. Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ (2010) Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 115:3632–3639. doi:10.1182/blood-2009-11-252643
63. Wei ZZ, Yu SP, Lee JH, Chen D, Taylor TM, Deveau TC, Yu AC, Wei L (2014) Regulatory role of the JNK-STAT1/3 signaling in neuronal differentiation of cultured mouse embryonic stem cells. Cell Mol Neurobiol 34:881–893. doi:10.1007/s10571-014-0067-4
64. Wirenfeldt M, Dissing-Olesen L, Anne Babcock A, Nielsen M, Meldgaard M, Zimmer J, Azcoitia I, Leslie RG, Dagnaes-Hansen F, Finsen B (2007) Population control of resident and immigrant microglia by mitosis and apoptosis. Am J Pathol 171:617–631